ReviewPharmacogenomics2009
EGFR-targeted therapies in lung cancer: predictors of response and toxicity.
Review in Pharmacogenomics, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 1 synthesis or guideline pooled it, 77 citations in OpenAlex.
- Incidence and risk of severe neutropenia in advanced cancer patients treated with cetuximab: a meta-analysis.Drugs in R&D · 2011Pooled it
- Erlotinib in African Americans with advanced non-small cell lung cancer: a prospective randomized study with genetic and pharmacokinetic analyses.Clinical pharmacology and therapeutics · 2014Trial
- EGFR pathway biomarkers in erlotinib-treated patients with advanced pancreatic cancer: translational results from the randomised, crossover phase 3 trial AIO-PK0104.British journal of cancer · 2013Trial
- Mutations in untranslated non-coding regions of EGFR, AKT1 & HRAS modulate their expression regulatory networks to facilitate progression of colorectal cancer.Functional & integrative genomics · 2026Article
- Circulating proteomic landscape of lung function.The European respiratory journal · 2026Article
- Polycationic dendrimers synergizes with gefitinib to overcome EGFRDiscover oncology · 2026Article
- Bispecific Siglec-15/T cell antibody (STAB) activates T cells and suppresses pancreatic ductal adenocarcinoma and non-small cell lung tumorsTheranostics · 2025Article
- Prevalence of single-nucleotide variants in twenty-five pharmacogenes from a Cuban sample cohort.Frontiers in pharmacology · 2024Article
- In Silico and In Vitro Exploration of Poziotinib and Olmutinib Synergy in Lung Cancer: Role of hsa-miR-7-5p in Regulating Apoptotic Pathway Marker Genes.Medicina (Kaunas, Lithuania) · 2023Article
- Article
- Zero-Background Small-Molecule Sensors for Near-IR Fluorescent Imaging of Biomacromolecular Targets in Cells.ACS sensors · 2023Article
- Emerging genetic biomarkers in lung adenocarcinoma.SAGE open medicine · 2022Review
- Immunotherapy and targeted therapy for lung cancer: Current status and future perspectives.Frontiers in pharmacology · 2022Review
- Impact of heavy smoking on the benefits from first-line EGFR-TKI therapy in patients with advanced lung adenocarcinoma.Medicine · 2018Observational
- IL6 is associated with response to dasatinib and cetuximab: Phase II clinical trial with mechanistic correlatives in cetuximab-resistant head and neck cancer.Oral oncology · 2017Article
- Emerging Roles of MicroRNAs in EGFR-Targeted Therapies for Lung Cancer.BioMed research international · 2015Review
- The relationship of kinase insert domain receptor gene polymorphisms and clinical outcome in advanced hepatocellular carcinoma patients treated with sorafenib.Medical oncology (Northwood, London, England) · 2014Article
- Article
- Incidence and risk of hypomagnesemia in advanced cancer patients treated with cetuximab: A meta-analysis.Oncology letters · 2013Article
- Pharmacogenetic predictors for EGFR-inhibitor-associated skin toxicity.The pharmacogenomics journal · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
The EGFR pathway has emerged as a key target in non-small-cell lung cancer. EGF receptor (EGFR) inhibition in non-small-cell lung cancer is achieved via small molecular tyrosine kinase inhibitors, such as erlotinib or gefitinib, or monoclonal antibodies such as cetuximab. A growing body of evidence is identifying potential molecular predictors of response and toxicity. This includes tumor-related molecular markers, such as EGFR mutation and copy number, as well as germline markers such as polymorphisms in EGFR or EGFR pathway-related genes. This review focuses on the current state of knowledge of predictors of response and toxicity to EGFR inhibitors in lung cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.